A leak of official documents from the Ministry of Health in Moscow, initially revealed by a Wall Street Journal investigation, details the outlines of a major national project in Russia. Named “New Health Preservation Technologies,” this program benefits from a $26 billion budget envelope allocated by the Kremlin.
The strategic objective displayed by the Russian authorities is to achieve tangible results by 2030, a deadline that now structures the country’s entire technological policy. Budgetary documents indicate that this initiative explicitly aims to save 175,000 lives by the end of the decade through disruptive medical breakthroughs.
Several independent observers put this figure into perspective with the Russian military losses recorded since the beginning of the conflict in Ukraine. The political genesis of this state program finds documented illustration during an official visit of Russian diplomacy to the People’s Republic of China.
A “hot mic” technical incident captured an informal exchange in Beijing between Vladimir Putin and his Chinese counterpart Xi Jinping. The two heads of state discussed contemporary research on cellular regeneration and the technical possibility of replacing failing organs to indefinitely prolong human life.
This private discussion quickly translated into a strict administrative doctrine within Russian ministries, turning the extension of life into a national priority. The government thus seeks to institutionalize gerontological research to make it a pillar of state power. This financial effort fits into a dynamic of global technological competition where the biology of longevity becomes a new attribute of sovereignty.
The Kremlin’s biotechnological arsenal
The operational implementation of this plan relies on the coordination of three major scientific axes defined by the Ministry of Digital Development and Health. The first axis involves the direct fight against cellular aging through advanced gene therapies targeting the mechanisms of senescence. On April 23, the Deputy Minister of Science and Higher Education, Denis Sekirinsky, publicly confirmed the launch of research protocols dedicated to inhibiting cellular decline.
State laboratories have been tasked with developing viral vectors capable of modifying gene expressions responsible for the degradation of human tissues. This research relies on centralized genetic databases compiled under government supervision over recent years. The objective is to design treatments that can be administered on a large scale to curb pathologies linked to the advanced age of the active population.
The second strategic pillar is based on the 3D bio-printing of complex tissues intended for structural regenerative medicine. Russian research teams have validated the first experimental phases by conducting tests on biosynthetic artificial cartilage. These laboratory-printed cellular structures are intended to replace damaged joints in patients suffering from degenerative diseases.
The third component, which is particularly complex on a biological level, concerns xenotransplantation technologies planned for clinical application by 2030. The program provides for the cultivation of organs compatible with the human body within breeding facilities of genetically modified mini-pigs. These animals undergo specific gene deletions to avoid immediate immune rejection during eventual transplantation into a human subject.
The integration of these technologies is the subject of documented analysis by international media specializing in the geopolitics of health. The investigative video from CNBC TV18 clarifies the interactions between organ bio-printing and the allocation of the $26 billion plan. This visual document highlights the industrial infrastructure mobilized by Moscow to realize these biological objectives.
The role of artificial intelligence and rosatom
The technical and industrial coordination of these various biological sectors is entrusted to state entities derived from the energy and defense sectors. The national nuclear energy corporation, Rosatom, directly pilots the infrastructure for xenotransplantation and tissue printing due to its expertise in handling precision materials. The state company applies the standards of nuclear physics to the logistics of cutting-edge biotechnologies.
Artificial intelligence serves as the central modeling tool to accelerate the discovery of therapeutic molecules and predict the protein folding essential for gene therapies. Supercomputers at Russian research institutes analyze cellular mutations at an industrial pace to identify the most promising anti-senescence targets. This massive processing of biological data aims to offset Russia’s technological lag behind Western laboratories.
Deep learning algorithms are also exploited to optimize immunological compatibility during animal organ transplantation experiments. Artificial intelligence simulates human immune system reactions to tissues derived from the mini-pigs modified by Rosatom. This convergence between heavy computing and molecular biology constitutes the operational core of the “New Health Preservation Technologies” initiative.
| Intervention Category | Examples of Fundamental Pillars | Role of Tech & Precision Data | Expected Biological Impact |
| Genetic Modification | • Development of anti-senescence viral vectors • Centralized state genetic databases | • AI-driven modeling of cell mutations • High-throughput screening of therapeutic molecules | • Inhibition of cellular decline • Modification of gene expressions linked to tissue degradation |
| 3D Bio-printing | • 3D printing of complex human tissues • Production of biosynthetic artificial cartilage | • Precision material engineering managed by Rosatom supercomputers | • Structural regenerative medicine • Replacement of joints damaged by degenerative diseases |
| Xenotransplantation | • Breeding facilities of genetically modified mini-pigs • Production of compatible organs by 2030 | • CRISPR genomic modification • AI simulation of human immune system reactions | • Prevention of immediate immune rejection • Mass production of “humanized” animal organs for transplant |
| Gerontological Integration | • Evolution of Khavinson’s calf peptide theories • State-backed biological research clusters | • Centralized budget direction ($26B) via Maria Vorontsova and Kurchatov Institute | • “Continuous repair of man” to counter demographic transition • Institutionalization of longevity as a national security asset |
A first circle of power mobilized
The direction and oversight of this state program are entrusted to the most influential figures in the Russian president’s immediate circle. Endocrinologist Maria Vorontsova, identified by Western diplomacies as Vladimir Putin’s eldest daughter, plays a leading role in the governance of the project. She directly supervises genetic research programs funded by special Kremlin funds and the presidential administration.
Her academic position and political connections allow her to centralize strategic decisions and direct budgets toward medical biology institutes in Moscow and Novosibirsk. The involvement of Maria Vorontsova guarantees the program absolute political protection and priority access to state financial resources. Her presence reassures the government regarding the confidentiality of research conducted within closed laboratories.
At the conceptual level, the project is theorized and promoted by physicist Mikhail Kovalchuk, director of the Kurchatov Institute and close scientific advisor to the head of state. Mikhail Kovalchuk publicly defends the doctrine of “the continuous repair of man,” a state transhumanist vision where technology must correct biological wear and tear. He presents biological longevity not as individual comfort, but as a national security imperative in the face of demographic transition.
This scientific orientation aligns with the historical continuity of the work of gerontologist Vladimir Khavinson, who passed away in early 2024. Vladimir Khavinson had made a name for himself through his research on calf peptides, molecules supposed to prolong the lifespan of high Soviet and then Russian dignitaries. His scientific legacy serves as the ideological and technical foundation for the new biological directions developed under the current plan.
The influence of the Soviet gerontological school remains perceptible in the Kremlin’s desire to tie biological research closely to the performance of the state apparatus. Vladimir Khavinson’s successors are attempting to modernize these old concepts by integrating contemporary tools of genomic modification using CRISPR. This scientific transition is taking place under the direct control of the Security Council of the Russian Federation.
Between real breakthroughs and scientific opacity
The implementation of this $26 billion plan raises significant reservations within the international scientific community due to its closed nature. The primary criticism formulated by foreign biologists concerns the near-total absence of peer-reviewed scientific publications in reference medical journals. Russian experimental protocols remain protected by state or military secrecy, which prevents any independent verification of the announced results.
This opacity fuels skepticism regarding the actual viability of xenotransplantation and gene therapy projects by 2030. Several experts emphasize the structural risk of grand announcements by Russian institute directors eager to secure their budget allocations. Faced with an executive power obsessed with the aging of its leaders and its population, the temptation is strong to oversell theoretical advances.
The Russian model of longevity thus positions itself in complete opposition to the Silicon Valley ecosystem, characterized by massive private investments. In the West, companies like Altos Labs or Calico depend on venture capital and must submit their discoveries to global scientific critique. The Kremlin’s project, entirely state-run and militarized in its management, primarily answers to objectives of geopolitical power and internal stability.
Excessive centralization of research around the Kurchatov Institute and the Rosatom corporation limits the scientific emulation that usually characterizes major biomedical innovations. Furthermore, international sanctions imposed on Russia restrict local laboratories’ access to sequencing equipment and fine chemical reagents produced in the West. This material constraint reinforces doubts about Moscow’s capacity to materialize its transhumanist ambitions within the timeframes set by the presidential schedule.
